Consolidated Statements of Cash Flows - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
| Cash flows from operating activities: |
|
|
|
| Net income (loss) including noncontrolling interests in operating subsidiaries |
$ (54,799)
|
$ (157,478)
|
$ (66,662)
|
| Adjustments to reconcile net income (loss) including noncontrolling interests in operating subsidiaries to net cash provided by (used in) operating activities: |
|
|
|
| Depreciation and amortization |
34,355
|
53,289
|
54,049
|
| Non-cash stock compensation |
9,062
|
11,048
|
18,115
|
| Provision for deferred income taxes |
0
|
0
|
(1,736)
|
| Impairment of Patent-Related Intangible Assets |
42,340
|
74,731
|
3,497
|
| Impairment of Goodwill |
0
|
30,149
|
0
|
| Other |
(477)
|
(109)
|
(28)
|
| Changes in assets and liabilities: |
|
|
|
| Increase (Decrease) in Restricted Cash |
(787)
|
(10,725)
|
0
|
| Accounts receivable |
6,750
|
(13,332)
|
(13,827)
|
| Prepaid expenses and other assets |
1,593
|
(619)
|
3,154
|
| Accounts payable and accrued expenses / costs |
(3,006)
|
2,570
|
3,718
|
| Royalties and contingent legal fees payable |
(970)
|
527
|
3,904
|
| Net cash provided by (used in) operating activities |
34,061
|
(9,949)
|
4,184
|
| Cash flows from investing activities: |
|
|
|
| Purchase of property and equipment |
(4)
|
(8)
|
(109)
|
| Purchase of available-for-sale investments |
(62,633)
|
(23,296)
|
(109,963)
|
| Sale of available-for-sale investments |
43,232
|
82,115
|
182,115
|
| Patent acquisition costs |
(1,225)
|
(19,504)
|
(42,746)
|
| Payments to Acquire Investments |
(20,000)
|
0
|
0
|
| Net cash provided by (used in) investing activities |
(40,630)
|
39,307
|
29,297
|
| Cash flows from financing activities: |
|
|
|
| Payments of Dividends |
0
|
(25,434)
|
(25,039)
|
| Distributions to noncontrolling interests in operating subsidiary |
(1,358)
|
(4,105)
|
(867)
|
| Proceeds from the exercise of stock options |
326
|
938
|
206
|
| Repurchases of common stock |
(82)
|
0
|
0
|
| Net cash provided by (used in) financing activities |
(1,114)
|
(28,601)
|
(25,700)
|
| Increase in cash and cash equivalents |
(7,683)
|
757
|
7,781
|
| Cash and cash equivalents, beginning |
135,223
|
134,466
|
126,685
|
| Cash and cash equivalents, ending |
127,540
|
135,223
|
134,466
|
| Patent acquisition costs included in accrued expenses |
$ 0
|
$ 1,000
|
$ 16,700
|